News - solanezumab, Research

Filter

Current filters:

solanezumabResearch

Popular Filters

Another Alzheimer's drug hits the dust as Bristol-Myers drops avagacestat development

04-12-2012

In yet another research disappointment, US drug major Bristol-Myers Squibb (NYSE: BMY) recently assessed…

avagacestatbapineuzumabBristol-Myers SquibbMK-8931NeurologicalPharmaceuticalResearchsolanezumab

Roche and Lilly drugs chosen for major Washington University Alzheimer's prevention trial

11-10-2012

Leading scientists at the USA's Washington University at St Louis have selected the first drugs to be…

BiotechnologyEli LillygantenerumabNeurologicalPharmaceuticalResearchRochesolanezumab

Mixed results with Eli Lilly Alzheimer's drug solanezumab, but investors pleased

09-10-2012

US pharma major Eli Lilly (NYSE: LLY) yesterday reported detailed results from two Phase III studies…

BiotechnologyEli LillyNeurologicalPharmaceuticalResearchsolanezumab

Mixed news on Lilly's Alzheimer's drug solanezumab; Alimta patent upheld

28-08-2012

US drug major Eli Lilly (NYSE: LLY) revealed last Friday that the primary endpoints, both cognitive and…

AlimtaEli LillyLegalNeurologicalNorth AmericaOncologyPatentsPharmaceuticalResearchsolanezumabTeva Pharmaceutical Industries

Company Spotlight

Eleven Biotherapeutics

Eleven Biotherapeutics

Back to top